37663-42-6

Basic information

• Product Name: 1''-BENZYL-3H-SPIRO[2-BENZOFURAN-1,4''-PIPERIDIN]-3-ONE
• Synonyms: 1''-BENZYL-3H-SPIRO[2-BENZOFURAN-1,4''-PIPERIDIN]-3-ONE;1'-Benzyl-3H-spiro[isobenzofuran-1,4'-piperidin]-3-one
• CAS NO: 37663-42-6
• Molecular Formula: C₁₉H₁₉NO₂
• Molecular Weight: 293.364
• Mol File: 37663-42-6.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1''-BENZYL-3H-SPIRO[2-BENZOFURAN-1,4''-PIPERIDIN]-3-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1''-BENZYL-3H-SPIRO[2-BENZOFURAN-1,4''-PIPERIDIN]-3-ONE(37663-42-6)
• EPA Substance Registry System: 1''-BENZYL-3H-SPIRO[2-BENZOFURAN-1,4''-PIPERIDIN]-3-ONE(37663-42-6)

Safety Data

• Hazardous Substances Data: 37663-42-6(Hazardous Substances Data)

Usage

General Description

1''-Benzyl-3H-spiro[2-benzofuran-1,4''-piperidin]-3-one, also known as BFPO, is a chemical compound with a unique spiro heterocyclic structure. It is a potential drug candidate with diverse pharmacological activities, including antiviral, analgesic, and antitumor properties. BFPO has been studied for its ability to inhibit the replication of the human immunodeficiency virus (HIV) and have analgesic effects in animal models. Additionally, it has shown potential as an antitumor agent, with studies demonstrating its ability to induce apoptosis in cancer cells. The unique and complex structure of BFPO makes it an interesting compound for further pharmaceutical research and potential drug development.

Upstream product

• 3612-20-2 1-phenylmethyl-4-piperidone 
• 88-65-3 2-bromobenzoic-acid 
• 693-04-9 butyl magnesium bromide 
• 610-97-9 o-iodo-methyl-benzoic acid 
• 54596-21-3 2-bromo-N-(2-hydroxy-1,1-dimethylethyl)benzamide 
• 398476-51-2 C₁₉H₂₁NO₂ 
• 93-98-1 N-phenyl benzoyl amide 

Downstream Products

• 172733-79-8 3-oxospiro[isobenzofuran-1(3H),4'-piperidine] hydrochloride 
• 1254981-82-2 1'-(benzyl)-spiro[isobenzofuran-1(3H),4'-piperidin]-3-thione 
• 56657-86-4 1'-[4,4-bis-(4-fluoro-phenyl)-butyl]-spiro[isobenzofuran-1,4'-piperidin]-3-one 
• 37663-46-0 1,3-dihydrospiro[isobenzofuran-1,4'-piperidine]-3-one 
• 37663-43-7 1'-benzylspiro[isobenzofuran-1(3H),4'-piperidine] 

Relevant articles and documents

A concise synthesis of 3,4-fused spiro[isobenzofuran-3-ones], spiro[furo[3,4-b]pyridin-5(7H)-ones], 3-aryl-, and alkylphthalides

A synthetically useful protocol has been developed for the preparation of highly functionalized 3,4-fused spiro[isobenzofuran-3-ones], spiro[furo[3,4-b]pyridin-5(7H)-ones], 3-aryl-, and alkylphthalides. Reaction of 2-iodobenzoate esters and 2-iodopyridine carboxylate esters with i-PrMgCl·LiCl in the presence of cyclic ketones under standard Barbier reaction conditions affords 3,4-fused spiro[isobenzofuran-3-ones] and spiro[furo[3,4-b]pyridin-5(7H)-ones] in good to excellent yields. Step-wise addition of i-PrMgCl·LiCl to 2-iodobenzoate esters followed by trapping with various aldehydes yields 3-aryl and 3-alkylphthalides; whereas, under similar conditions access to 3-aryl and 3-alylazaphthalides is also possible. Extension of this methodology toward the preparation of 3-n-butylphthalide and chrycolide, a natural product isolated from the leaves and stems of Chrysanthemum coronarium, is also described.

Design, syntheses, and structure-activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4′-piperidin]-1′-yl}benzimidazole derivatives

Design, syntheses, and structure-activity relationships of a novel class of 2-{3-oxospiro[isobenzofuran-1(3H),4′-piperidin]-1′-yl}benzimidazole NPY Y5 receptor antagonists are described. The benzimidazole structures were newly designed based on the urea linkage of our prototype Y5 receptor antagonists (2 and 3). By optimizing substituents on the benzimidazole core part of the lead compound 5a, we were able to develop a potent, orally available, and brain-penetrable Y5 selective antagonist (5k). Crown Copyright

MODULATORS OF MUSCARINIC RECEPTORS

The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.